Biotage triples its production capacity for equipment crucial in the supply chain for the production of mRNA vaccines.

New Facility Helps Reduce COVID-19 Vaccine Bottlenecks

Aug 24 2021

Biotage triples production capacity for supply chain equipment vital for mRNA vaccine production

The availability of raw materials for mRNA vaccine production has been a major bottleneck as the lipids that were needed for new LNP (Lipid Nano Particles formulations used in mRNA vaccines) were not previously available on the scale needed to produce billions of doses of vaccine globally. The rapid development of a scalable and reliable route into commercial production of these lipids has been made possible with the aid of Biotage’s flash purification platforms, systems and expertise.

Expanded Cardiff production facility now fully operational

Expanding its production capacity of large-scale flash columns by 300%, Biotage is now helping pharmaceutical companies and contract manufacturers’ scale up lipid production for COVID-19 vaccines. A new, bespoke production facility is now operational at the Biotage site in Cardiff, UK.
“Our customers needed to manufacture their products on a significantly larger scale, and we were able to invest in an expansion of our existing production facilities to support their requirements. We were very pleased to be able to deliver this expansion in just over four months in order to meet the needs of present and potential new clients,” commented Anders Wikström, EVP Operations of Biotage.
The newly opened production facility will enable Biotage to meet the increase in demand for this vital market segment, without any disruption to existing clients already producing APIs, fine chemicals, natural products or in other markets.
“This initiative is an example of how Biotage has a positive impact on society in line with our ethos HumanKind Unlimited. At the same time, it proves that we have a keen ear to our customers’ needs and have built an organisation capable of moving quickly to meet new demand in rapidly growing niche markets within the pharmaceutical industry,” said Tomas Blomquist, CEO and President of Biotage.

More information online